ATE481399T1 - Verfahren zur in-situ chemischer sulfonierung - Google Patents

Verfahren zur in-situ chemischer sulfonierung

Info

Publication number
ATE481399T1
ATE481399T1 AT09152654T AT09152654T ATE481399T1 AT E481399 T1 ATE481399 T1 AT E481399T1 AT 09152654 T AT09152654 T AT 09152654T AT 09152654 T AT09152654 T AT 09152654T AT E481399 T1 ATE481399 T1 AT E481399T1
Authority
AT
Austria
Prior art keywords
situ chemical
sulfonation
chemical sulfonation
situ
chemical
Prior art date
Application number
AT09152654T
Other languages
English (en)
Inventor
Joergen Blixt
Michael Golden
Philip Hogan
David Martin
Francis Montgomery
Zakariya Patel
John Pittman
George Sependa
Christopher Squire
Nicholas Wright
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE481399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE481399T1 publication Critical patent/ATE481399T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT09152654T 2005-09-30 2006-09-27 Verfahren zur in-situ chemischer sulfonierung ATE481399T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0519879.1A GB0519879D0 (en) 2005-09-30 2005-09-30 Chemical process

Publications (1)

Publication Number Publication Date
ATE481399T1 true ATE481399T1 (de) 2010-10-15

Family

ID=35395001

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06794582T ATE448218T1 (de) 2005-09-30 2006-09-27 Chemisches verfahren
AT09152654T ATE481399T1 (de) 2005-09-30 2006-09-27 Verfahren zur in-situ chemischer sulfonierung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT06794582T ATE448218T1 (de) 2005-09-30 2006-09-27 Chemisches verfahren

Country Status (31)

Country Link
US (8) US8163926B2 (de)
EP (2) EP2053048B8 (de)
JP (2) JP5213715B2 (de)
KR (1) KR101307641B1 (de)
CN (3) CN102503898B (de)
AR (1) AR055671A1 (de)
AT (2) ATE448218T1 (de)
AU (1) AU2006296367B2 (de)
BR (1) BRPI0616715A2 (de)
CA (2) CA2745829C (de)
CY (2) CY1110275T1 (de)
DE (2) DE602006010428D1 (de)
DK (2) DK1943240T3 (de)
ES (2) ES2335435T3 (de)
GB (1) GB0519879D0 (de)
HR (2) HRP20100019T1 (de)
IL (2) IL190172A (de)
ME (2) ME01531B (de)
MY (2) MY149834A (de)
NO (1) NO342152B1 (de)
NZ (2) NZ566566A (de)
PL (2) PL2053048T3 (de)
PT (2) PT1943240E (de)
RS (2) RS51263B (de)
RU (1) RU2448102C2 (de)
SG (1) SG165416A1 (de)
SI (2) SI2053048T1 (de)
TW (2) TWI424991B (de)
UY (1) UY29824A1 (de)
WO (1) WO2007036713A2 (de)
ZA (1) ZA200802416B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2365588C2 (ru) * 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
EP2404595B1 (de) * 2011-09-01 2015-08-05 Symrise AG Verfahren zur Herstellung von Indanon-Derivaten
ES2678697T3 (es) * 2012-08-15 2018-08-16 Glaxo Group Limited Proceso químico
CN104098544A (zh) * 2013-04-07 2014-10-15 浙江九洲药物科技有限公司 一种凡德他尼的制备方法
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870083A (en) 1987-11-24 1989-09-26 Merrell Dow Pharmaceuticals Inc. 1,4-Disubstituted-piperidinyl compounds useful as analgesics and muscle relaxants
JP2829744B2 (ja) 1989-05-31 1998-12-02 川研ファインケミカル株式会社 ピペリジンカルボン酸類の製造方法
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JP2659107B2 (ja) 1991-03-28 1997-09-30 エーザイ株式会社 複素環式―環式アミン誘導体
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DK0584222T3 (da) 1991-05-10 1998-02-23 Rhone Poulenc Rorer Int Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
US5624926A (en) 1993-02-18 1997-04-29 Kyowa Hakko Kogyo Co., Ltd. Piperidinyl-dioxoquinazolines as adenosine reuptake inhibitors
ES2121210T3 (es) * 1993-05-26 1998-11-16 Syntex Inc Nuevos ligandos de receptores 5-ht4 a base de 1-fenilalcan-1-onas.
DE4326344A1 (de) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995019344A1 (en) 1994-01-13 1995-07-20 Merck Sharp & Dohme Limited Gem-disubstituted azacyclic tachykinin antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CN1116286C (zh) 1996-03-05 2003-07-30 曾尼卡有限公司 4－苯胺基喹唑啉衍生物
CA2265630A1 (en) 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
EP1676845B1 (de) * 1999-11-05 2008-06-11 AstraZeneca AB Neue Quinazolin-Derivate
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
EP1467995B1 (de) 2001-12-20 2010-05-19 OSI Pharmaceuticals, Inc. Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
RU2365588C2 (ru) 2002-02-01 2009-08-27 Астразенека Аб Хиназолиновые соединения
AU2003207291A1 (en) 2002-02-06 2003-09-02 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
EP1534287A1 (de) 2002-08-09 2005-06-01 Astrazeneca AB Kombination von zd6474, einem inhibitor des vaskulären endothelialen wachstumsfaktorrezeptors, mit radiotherapie für die behandlung von krebs
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
SI1592423T1 (sl) 2003-02-13 2011-07-29 Astrazeneca Ab Kombinacijska terapija ZD6474 s 5-FU in/ali CPT-11
WO2005004870A1 (en) 2003-07-10 2005-01-20 Astrazeneca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
GB0519879D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process

Also Published As

Publication number Publication date
TWI328580B (en) 2010-08-11
DE602006017004D1 (de) 2010-10-28
CA2624045A1 (en) 2007-04-05
CN102503898B (zh) 2015-03-25
PT1943240E (pt) 2010-01-11
ATE448218T1 (de) 2009-11-15
NO20081267L (no) 2008-04-30
IL227574A (en) 2015-08-31
DK1943240T3 (da) 2010-03-01
CN101277948A (zh) 2008-10-01
JP2013063998A (ja) 2013-04-11
RS51515B (sr) 2011-06-30
US9815816B2 (en) 2017-11-14
EP2053048A1 (de) 2009-04-29
ES2335435T3 (es) 2010-03-26
AR055671A1 (es) 2007-08-29
RS51263B (sr) 2010-12-31
CN102503898A (zh) 2012-06-20
CN102503933B (zh) 2014-06-25
US20190263782A1 (en) 2019-08-29
DK2053048T3 (da) 2010-11-29
US20120095229A1 (en) 2012-04-19
CA2624045C (en) 2012-05-22
WO2007036713A2 (en) 2007-04-05
CA2745829A1 (en) 2007-04-05
US8163926B2 (en) 2012-04-24
NZ566566A (en) 2011-08-26
CN101277948B (zh) 2013-03-13
PT2053048E (pt) 2010-11-10
HK1122553A1 (en) 2009-05-22
EP2053048B1 (de) 2010-09-15
EP1943240B1 (de) 2009-11-11
GB0519879D0 (en) 2005-11-09
US20240150317A1 (en) 2024-05-09
SI1943240T1 (sl) 2010-02-26
PL2053048T3 (pl) 2011-03-31
NO342152B1 (no) 2018-04-03
US10344015B2 (en) 2019-07-09
CN102503933A (zh) 2012-06-20
EP2053048B8 (de) 2011-09-21
JP5213715B2 (ja) 2013-06-19
CY1110275T1 (el) 2015-01-14
UY29824A1 (es) 2007-04-30
US20160185754A1 (en) 2016-06-30
ME01466B (me) 2014-04-20
HK1130478A1 (en) 2009-12-31
RU2448102C2 (ru) 2012-04-20
JP5654546B2 (ja) 2015-01-14
JP2009510039A (ja) 2009-03-12
HRP20100019T1 (hr) 2010-02-28
EP1943240A2 (de) 2008-07-16
SI2053048T1 (sl) 2010-12-31
ME01531B (me) 2014-04-20
US20140378684A1 (en) 2014-12-25
MY145540A (en) 2012-02-29
US20220033377A1 (en) 2022-02-03
WO2007036713A3 (en) 2007-06-14
IL190172A0 (en) 2008-08-07
US8865899B2 (en) 2014-10-21
HRP20100620T1 (hr) 2010-12-31
US20180118716A1 (en) 2018-05-03
CA2745829C (en) 2013-07-02
BRPI0616715A2 (pt) 2011-06-28
NZ593930A (en) 2013-02-22
DE602006010428D1 (de) 2009-12-24
AU2006296367A1 (en) 2007-04-05
TWI424991B (zh) 2014-02-01
RU2008116573A (ru) 2009-11-10
TW200745036A (en) 2007-12-16
US20090203905A1 (en) 2009-08-13
KR20080049114A (ko) 2008-06-03
SG165416A1 (en) 2010-10-28
ES2350513T3 (es) 2011-01-24
TW201018660A (en) 2010-05-16
IL190172A (en) 2014-05-28
MY149834A (en) 2013-10-31
ZA200802416B (en) 2009-01-28
AU2006296367B2 (en) 2011-08-11
CY1110887T1 (el) 2015-06-10
PL1943240T3 (pl) 2010-04-30
KR101307641B1 (ko) 2013-09-12

Similar Documents

Publication Publication Date Title
AT505197A3 (de) Verfahren zur aktivierung eines photosensibilisators
ATE544933T1 (de) Verfahren zur kohlenwasserstoff-reservoir- überwachung
DE602004006598D1 (de) Verfahren zur drahtlosen Datenübertragung
DE602007004783D1 (de) Verfahren zur Reinigung von Photomasken
DE602005010348D1 (de) Verfahren zur schnurlosen Datenübertragung
DE602006005607D1 (de) Verfahren zur färbung einer kontaktlinse
DE602006002419D1 (de) Eintauchverfahren
DE502006003630D1 (de) Verfahren zum ermitteln einer inhomogenen fahrbahn
DE602006020089D1 (de) Verfahren zur CVI
DE102007044925B8 (de) Verfahren zur Stillstands-/Bewegungsbestimmung von Fahrzeugen
DE602006007648D1 (de) Verfahren zur implementierung der zugriffsbereichs
DE502006005802D1 (de) Verfahren zum fertigen von bohrungen
DE502005010287D1 (de) Verfahren zur hydrocyanierung
DE602006006586D1 (de) Verfahren zum sicheren Klassifizieren privater Daten
DE502005003641D1 (de) Verfahren zur drahtlosen Datenübertragung
ATE481399T1 (de) Verfahren zur in-situ chemischer sulfonierung
ATE430716T1 (de) Verfahren zur reinigung einer wässrigen lösung
ATE394369T1 (de) Verfahren zur aufreinigung von mesotrion
DE502006006353D1 (de) Verfahren zur hydrosilylierung
DE602006010858D1 (de) Verfahren zur handhabung sperrenbedingter inkonsistenzen
ATE482992T1 (de) Verfahren zur pastillierung von stabilisator- schmelzen
DE502005008598D1 (de) Verfahren zur übermittlung von kommunikationsdaten
FI20055615A7 (fi) Menetelmä aineiden poistamiseksi vesiliuoksesta
DE602006020121D1 (de) Verfahren zum untersuchen von brillenlinsen
DE602004010396D1 (de) Verfahren zur Sulfierung von Chondroitin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2053048

Country of ref document: EP